BUDGET IMPACT EVALUATION OF A PNEUMOCOCCAL CONJUGATED VACCINE (PCV) 13 VALENT VACCINATION WITH FREE CAMPAIGN PROGRAM FOR CORPORATIONS VESUS NO VACCINATION FOR OLDER ADULTS

被引：0
|
作者：
Fujii, R. K. [1 ]
Presa, J. [1 ]
Roberts, C. S. [2 ]
Gea, Y. [1 ]
Manfrin, D. F. [1 ]
Mould, J. [2 ]
机构：
[1] Pfizer Inc, Sao Paulo, Brazil
[2] Pfizer, New York, NY USA
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 03期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A84 / A84
页数：1
相关论文
共 50 条
  • [21] A cost-effectiveness study of a universal vaccination program with the 7-valent pneumococcal vaccine (PCV-7) in Sweden
    Bergman, A. S. C.
    Hjelmgren, J.
    Wisloff, T. F.
    Kristiansen, I. S.
    Persson, U.
    VALUE IN HEALTH, 2007, 10 (06) : A443 - A443
  • [22] MODELLING BUDGET IMPACT (BI) OF VACCINATING AT-RISK ADULTS AND THE ELDERLY WITH 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) COMPARED TO 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) IN GERMANY
    Jiang, Y.
    Gauthier, A.
    Annemans, L.
    van der Linden, M.
    Nicolas-Spony, L.
    Bresse, X.
    VALUE IN HEALTH, 2011, 14 (07) : A268 - A268
  • [23] COST EFFECTIVENESS ANALYSIS OF VACCINATION WITH 13-VALENT (PCV13) AND 23-VALENT (PPSV23) PNEUMOCOCCAL VACCINES FOR ADULTS IN COLOMBIA
    Nunez, S. M.
    Mould-Quevedo, J. F.
    Gutierrez-Ardila, M., V
    Roberts, C. S.
    La Rotta, J. E.
    VALUE IN HEALTH, 2012, 15 (04) : A242 - A242
  • [24] Economic evaluation of vaccination programme of 13-valent pneumococcal conjugate vaccine to the birth cohort in Japan
    Hoshi, Shu-ling
    Kondo, Masahide
    Okubo, Ichiro
    VACCINE, 2013, 31 (25) : 2762 - 2771
  • [25] Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults
    Stacey, Helen L.
    Rosen, Jeffrey
    Peterson, James T.
    Williams-Diaz, Angela
    Gakhar, Vanita
    Sterling, Tina M.
    Acosta, Camilo J.
    Nolan, Katrina M.
    Li, Jianing
    Pedley, Alison
    Benner, Patrice
    Abeygunawardana, Chitrananda
    Kosinski, Michael
    Smith, William J.
    Pujar, Hari
    Musey, Luwy K.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (03) : 530 - 539
  • [26] MODELED OUTCOMES AND OVERALL COSTS OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN THE TUNISIAN NATIONAL VACCINATION PROGRAM
    Zigmond, J.
    Pecen, L.
    Tichopad, A.
    Roberts, C. S.
    Jomaa, I
    VALUE IN HEALTH, 2014, 17 (07) : A607 - A608
  • [27] COST EFFECTIVENESS ANALYSIS OF VACCINATION WITH 13-VALENT (PCV13) AND 23-VALENT (PPV23) PNEUMOCOCCAL VACCINES FOR SENIOR ADULTS IN BRAZIL
    Fujii, R. K.
    Mould, J. F.
    Presa, J.
    Jardim, E.
    Sato, R.
    Strutton, D. R.
    VALUE IN HEALTH, 2011, 14 (07) : A279 - A279
  • [28] COST-EFFECTIVENESS ANALYSIS OF JOINT VACCINATION WITH 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) AND INFLUENZA VACCINE IN TAIWAN DURING SEASONAL INFLUENZA
    Wu, D. B. C.
    Chong, H. Y.
    Lee, K. K. C.
    VALUE IN HEALTH, 2014, 17 (03) : A273 - A273
  • [29] ALLOCATING VACCINE FUNDS FOR PNEUMOCOCCAL VACCINATION OF INFANTS AND OLDER ADULTS: A METHOD FOR STRATEGIC EVALUATION IN THE NETHERLANDS
    Delgleize, E.
    Standaert, B.
    VALUE IN HEALTH, 2014, 17 (07) : A676 - A676
  • [30] A BUDGET-IMPACT ANALYSIS (BIA) OF IMMUNIZING ADULTS WITH COPD WITH THE 13-VALENT VACCINE (PCV13) AGAINST COMMUNITY- ACQUIRED PNEUMONIA AND PNEUMOCOCCAL DISEASE
    Walter, E.
    Lazic-Peric, A.
    Schalle, K.
    VALUE IN HEALTH, 2017, 20 (09) : A783 - A783
12345